MONIQUE PHAN: Open Payments
NPI 1144005166 · SUN CITY, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,027 in 50 payments from 15 companies in 2025. Trend: 2023 $194 · 2024 $1,216 · 2025 $1,027
Food & beverage: $1,027
| Company | Payments | Amount |
|---|---|---|
| Sumitomo Pharma America, Inc. | 9 | $248 |
| Lilly USA, LLC | 9 | $132 |
| GlaxoSmithKline, LLC. | 5 | $97 |
| AstraZeneca Pharmaceuticals LP | 5 | $81 |
| Astellas Pharma US Inc | 3 | $76 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $74 |
| Medtronic, Inc. | 1 | $64 |
| Novo Nordisk Inc | 3 | $58 |
| Corcept Therapeutics | 2 | $53 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $31 |
Products named: GEMTESA, TRELEGY ELLIPTA, Veozah, XIFAXAN, JARDIANCE, KYPHON EXPRESS II KYPHOPAK TRAY, Korlym, BREZTRI.
Industry payments across AZ — which companies pay providers there.
